Whether the proposed derivative settlement was fair and reasonable to Caremark and its stockholders.
Holding
Yes. The settlement's prospective compliance reforms were modest but adequate because the underlying derivative claims were exceptionally weak.
Reasoning
A court approving a derivative settlement does not resolve disputed facts as it would after trial. Instead, it evaluates the relative strength of the claims and defenses on the discovery record, while protecting the corporation and absent stockholders whose claims will be released. The parties seeking approval bear the burden of showing that the compromise is fair and reasonable.
The settlement required Caremark to strengthen and formalize its compliance structure. It prohibited referral-based remuneration, required disclosures of financial relationships with referring providers, created a Compliance and Ethics Committee, required periodic compliance reports, and imposed contract-review duties. These reforms produced some benefit, although the court regarded them as limited because Caremark had already established a functioning compliance committee and had implemented related reforms.
The adequacy of settlement consideration depends importantly on the probable value of the released claims. Here, the record gave the stockholders little realistic prospect of recovering from the directors. In light of that weakness, even modest governance and compliance benefits were sufficient consideration for releasing the derivative claims.】【。},{